Importantly, the pharmacological inhibition of PHF8 with daminozide synergized with anti-PD1 antibody in vivo, leading to increased tumor infiltration with CD4+ and CD8+ T cells, and slower CRC tumor growth [117]. Here, CD8A is linked to neoplasm.